NCT01068327View on ClinicalTrials.gov

Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 5, 2007

Primary Completion Date

August 1, 2013

Study Completion Date

February 1, 2015

Conditions

Adenocarcinoma of the PancreasStage III Pancreatic Cancer

Interventions

DRUG

gemcitabine hydrochloride

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

fluorouracil

Given IV

DRUG

nelfinavir mesylate

Given PO

RADIATION

stereotactic body radiation therapy

Undergo radiotherapy

RADIATION

hypofractionated radiation therapy

Undergo radiotherapy

PROCEDURE

therapeutic conventional surgery

Undergo surgery

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER

NCT01068327 - Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter